单克隆丙种球蛋白病在慢性淋巴细胞白血病中定义跨越治疗时代的不同临床亚群
该回顾性分析纳入1999至2024年2075例慢性淋巴细胞白血病(CLL)患者,18.47%检出单克隆丙种球蛋白病(MG),IgM、IgG、轻链和IgA亚型呈现不同临床基因组特征;IgM-MG与更差的无进展生存和总生存相关,且靶向治疗未带来显著生存获益。
要点
- CLL患者中MG检出率为18.47%,以IgM(8.18%)和IgG(8.09%)亚型为主。
- IgM-MG与未突变IGHV、TP53异常及MYD88、BIRC3、DDX3X突变富集相关。
- IgM-MG患者接受靶向治疗较传统方案未获得显著生存获益。
核心结论
- MG亚型尤其是IgM-MG定义了CLL在生物学和临床上不同的亚群。
- 鉴于Bruton酪氨酸激酶抑制剂在IgM-MG中疗效有限,基于免疫固定电泳的MG分型可能有助于风险适应治疗策略和个体化治疗选择。
研究设计与样本
- 回顾性分析纳入1999至2024年2075例CLL患者,检测MG并分析其亚型分布、临床基因组特征及与治疗结局的关系。
主要发现
- MG在18.47%的CLL病例中检出,IgM占8.18%、IgG占8.09%、轻链型占1.14%、IgA占1.06%。
- IgA-MG患者诊断时年龄更大,IgG-MG患者年龄更轻且突变型IGHV频率更高。
- IgM-MG与未突变IGHV、乳酸脱氢酶和β2微球蛋白水平升高、TP53异常频率更高及MYD88、BIRC3、DDX3X突变富集相关。
- IgG-MG仅与至首次治疗时间(TTFT)缩短相关,而IgM-MG与TTFT、无进展生存和总生存显著更差相关。
- 亚组分析显示MG的不良预后影响在IGHV突变型CLL中明显,在未突变病例中减弱;CLL-IPI的预后区分能力不受MG状态影响。
关键数值与推荐
- MG总检出率为18.47%,其中IgM 8.18%、IgG 8.09%、轻链型1.14%、IgA 1.06%。
临床怎么用
- 作者认为基于免疫固定电泳的MG分型可能有助于风险适应治疗策略和个体化治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal gammopathy (MG) in chronic lymphocytic leukemia (CLL) portends heterogeneous outcomes, yet its molecular drivers and therapeutic implications remain undefined. In this retrospective analysis of 2075 patients with CLL (1999-2024), MG was detected in 18.47% cases, with immunoglobulin M (IgM) (8.18%), IgG (8.09%), light-chain (1.14%), and IgA (1.06%) subtypes demonstrating divergent clinicogenomic profiles. Patients with IgA-MG were older at diagnosis, whereas those with IgG-MG had a younger age and a higher frequency of mutated immunoglobulin heavy-chain variable (IGHV). In contrast, IgM-MG was associated with unmutated IGHV, elevated lactate dehydrogenase and β2-microglobulin levels, higher frequencies of TP53 aberrations, and enrichment of MYD88, BIRC3, and DDX3X mutations. IgG-MG was associated with shorter time-to-first treatment (TTFT) only, whereas IgM-MG correlated with significantly inferior TTFT, progression-free survival, and overall survival. Subgroup analyses revealed that the adverse prognostic impact of MG was pronounced in IGHV-mutated CLL but attenuated in unmutated cases. Prognostic discrimination by the CLL-International Prognostic Index (CLL-IPI) remained robust regardless of MG status. Notably, patients with IgM-MG did not experience significant survival benefit from targeted therapy compared with conventional regimens. These findings demonstrate that MG subtypes, particularly IgM-MG, define biologically and clinically distinct subsets of CLL. Given the limited efficacy of Bruton tyrosine kinase inhibitors in IgM-MG, immunofixation-based MG profiling may inform risk-adapted treatment strategies and personalized therapy selection.
引用
- Yan Y, Yuan B, Qiu T, et al. Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras. Blood Adv. 2025. PMID: 40902084. doi:10.1182/bloodadvances.2025017057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。